← Back to all signals
RESEARCH PAPER ANALYSIS

Functional Reorganization of Corticostriatal Connectivity Across the Degree of Nigrostriatal Degeneration in Parkinson Disease.

Multimodal imaging of >300 PD-spectrum participants reveals stage-dependent corticostriatal reorganization: early hyperconnectivity between the posterior caudate and primary motor cortex peaking around ~50% putaminal dopamine loss, and progressive loss of posterior putamen–posterior cortical…

PMID41996661
JournalNeurology
Publication Date2026-05-26
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Multimodal imaging of >300 PD-spectrum participants reveals stage-dependent corticostriatal reorganization: early hyperconnectivity between the posterior caudate and primary motor cortex peaking around ~50% putaminal dopamine loss, and progressive loss of posterior putamen–posterior cortical…

WHY IT MATTERS

Research significance

Provides stage-specific functional circuit biomarkers that can inform disease staging and the timing/targets for circuit-level interventions (e.g., neuromodulation) despite limited direct molecular or druggable targets.

ABSTRACT

Source abstract

BACKGROUND AND OBJECTIVES: In Parkinson disease (PD), deafferentation of nigral dopaminergic neurons to the striatum leads to striatal dopamine depletion and impaired direct and indirect basal ganglia pathways, which in turn reduce thalamocortical excitation and ultimately lead to parkinsonism. Therefore, understanding the manifestation of motor deficits requires the evaluation of degree of striatal dopamine depletion and the related changes in striatal functional connectivity (FC) as the nigrostriatal system degenerates. METHODS: In this cross-sectional study, we recruited 326 patients with PD and 29 patients with idiopathic REM sleep behavior disorder who underwent brain resting-state functional MRI, N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane PET, and the Unified Parkinson's Disease Rating Scale assessment. A total of 40 healthy controls (HCs) were recruited to determine the extent of striatal dopamine depletion in patients with PD spectrum, and another 40 HCs were recruited to compare corticostriatal FC with that of the patient group. Using a sliding window method, we examined changes in FC with seed regions in the anterior and posterior caudate and putamen on both the more affected and less affected sides as the mean putaminal dopamine declined from 70% to 20%. RESULTS: The more affected side of the posterior caudate showed elevated FC with the primary motor cortex and paracentral lobule, which was present before approximately 50% putaminal dopamine depletion, peaked around this depletion level, and disappeared when caudate dopamine was abnormally reduced. The more affected side of the posterior putamen showed reduced FC with the superior parietal cortex, precuneus, and cuneus when putaminal dopamine depletion reached approximately 50%, after which the motor symptoms deteriorated linearly. DISCUSSION: In summary, our study demonstrated that the FC between the posterior caudate and primary motor cortex was elevated from the prodromal to early stages of PD, a period in which motor symptom progression remained relatively slow. The FC between the posterior putamen and motor cortex remained unchanged, while its connectivity with the posterior cortical regions declined from the onset of motor symptoms, coinciding with the accelerated progression of motor deterioration. Collectively, our study demonstrated that corticostriatal connectivity undergoes functional reorganization across the different stages of PD, which is associated with motor symptoms.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic